BIOXIS Pharmaceuticals – Trademark Portfolio
Entity Type: 16
BIOXIS Pharmaceuticals holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BIOESTHÉ. The owner is based in Lyon.
317 Avenue Jean Jaurès
Lyon 69007 , FR
Showing of trademarks Trademarks
Trademark Classifications
BIOXIS Pharmaceuticals's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does BIOXIS Pharmaceuticals have?
BIOXIS Pharmaceuticals has 6 U.S. trademarks filed with the USPTO. Of these, 2 registered, 3 abandoned.
What trademark classes does BIOXIS Pharmaceuticals file in?
BIOXIS Pharmaceuticals files trademarks across 5 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 21 (Housewares). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are BIOXIS Pharmaceuticals's most well-known trademarks?
BIOXIS Pharmaceuticals's registered trademark portfolio includes well-known marks such as BIOESTHÉ. These are among 2 currently registered trademarks in the portfolio.
What is BIOXIS Pharmaceuticals's trademark registration success rate?
BIOXIS Pharmaceuticals has a 40% trademark registration rate, with 2 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.